Imaging, QoL and Patient-Reported Outcome and Supportive Care

P-101: Burden of AL Amyloidosis and its Association with Cardiac Involvement: Initial Results from a Patient-Reported Outcome Survey

P-102: Ocular complications are common in patients with multiple myeloma receiving dexamethasone: Results of a cross-sectional patient survey

P-103: Real World Data on Efficacy and Safety of Low-Dose Direct Oral Anticoagulants (DOACs) for Venous Thromboembolism (VTE) Prophylaxis in Newly Diagnosed Multiple Myeloma

P-104: Empowering Multiple Myeloma Patients: Impact of MMRF Education Programs and Results Of Patient Outcomes

P-105: PET/CT has prognostic significance for CAR T cell therapy in relapsed/refractory multiple myeloma

P-106: Assessment of quality of life, frailty, socioeconomic status and clinical characteristics of patients with multiple myeloma

P-107: EXPLORING THE ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

P-108: EXPLORING THE ROLE OF THE COMBINATION OF FDG-PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

P-109: GASTROINTESTINAL HISTOPLASMOSIS IN A PATIENT WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION: ORAL ULCER DIFFERENTIAL DIAGNOSIS. CASE REPORT.

P-110: Guillain-Barré syndrome following autologous stem cell transplantation for the treatment of multiple myeloma: a myth?

P-111: An orthopedic consultation and exercise intervention in patients with multiple myeloma during induction therapy: the randomized controlled GMMG-HD8-INDEX trial

P-112: Fall risk assessment and fall prevention in patients with multiple myeloma: first results of the MYFALL-trial

P-113: An artificial intelligence-based 3D-segmentation assessment of sarcopenia utilizing whole-body computed tomography in patients with multiple myeloma

P-114: MULTIPLE MYELOMA ASSOCIATED WITH OTHER PRIMARY MALIGNANT NEOPLASMS: EPIDEMIOLOGICAL CHARACTERISTICS OVER 20 YEARS OF HOSPITAL CANCER REGISTRY

P-115: Safety of a Cannabis-based oil for patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: protocol of a phase I/II study.

P-116: CHEMOTHERAPY RELATED NAUSEA AND VOMITING PROPHYLAXIS WITH APREPITANT FOR PATIENTS RECEIVING HIGH DOSE MELPHALAN FOLLOWED BY HSCT: A COST UTILITY ANALYSIS (CUA)

P-117: How do patients feel about how, when and where they get their treatments? A European survey of myeloma patients

P-118: Real-life data on patients with Multiple Myeloma (MM) and initiative to implement MM oncology navigation in the macro-region of Araçatuba-SP

P-119: Treatment Outcomes of Primary vs. Referred Patients with Multiple Myeloma Receiving Talquetamab or Teclistamab

P-120: Diagnostic Value of Echocardiography in Multiple Myeloma Complicated with Cardiac Amyloidosis

P-121: Prevalence of multiple myeloma in Ecuadorian hemodialysis units. A SEN study

P-122: A Comprehensive Analysis of Jawbone Destruction in Multiple Myeloma: Tomographic Perspectives from a Series of Cases

P-123: Patient Preferences for use of CAR-T therapy as an Early Line Treatment in Multiple Myeloma

P-124: Trends in survival and causes of death in multiple myeloma: a single-institution experience

P-125: Combination of geriatric assessment and clinical factors to predict the survival of elderly patients with myeloma

P-126: Characteristics and outcomes of patients with Multiple Myeloma aged ≤ 40 years – Experience from a Tertiary Care Cancer Centre in India

P-127: The role of spinal bracing in the management of Multiple Myeloma Spinal and Sternum disease

P-128: 68Ga-Pentixafor PET/CT-based response assessment in multiple myeloma patients and its comparison with 18F-FDG PET/CT and IMWG based clinical response.

P-129: Infections in newly diagnosed multiple myeloma : Incidence, characteristics, and outcome in a tertiary health care centre in India.

P-130: Diarrhea in multiple myeloma autologous stem cell transplant recipients: Think beyond mucositis!!

P-131: Cyclosporine as a rescue therapy for Primary Graft failure in Myeloma Autologous transplant

P-132: Daratumumab treatment in the patients’ own home.

P-135: Evaluating Racial Differences in the Systemic Impact of Monoclonal Protein in Multiple Myeloma Using Machine Learning

P-136: External Validation of a Machine Learning Model for Rapid Prediction of M-Spike Values in Multiple Myeloma Using the HealthTree Database

P-137: Optimizing Feature Selection for Large Language Models in AI-Assisted Clinical Assessment of Multiple Myeloma

P-138: Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma

P-139: 'Perceptions of Brazilian Hematologists in the Care of Patients with Multiple Myeloma in the Unified Health System: Brazil of Contrasts

P-140: Risk and incidence of venous thromboembolism in newly diagnosed Multiple Myeloma patients

P-141: Early Mortality in Newly Diagnosed Multiple Myeloma: Incidence and Risk Factors in an Indian Cohort

P-142: Clinical – epidemiologic features and disparities in access to diagnostic tools and novel therapies for MM Patients in Public and Private Health Care – A Comparative Analysis of 2 Hospitals in Brazil.

P-143: Enhancing psychosocial support for Multiple Myeloma patients in Moi Teaching and Referral Hospital (MTRH) Kenya.

P-144: Oral Symptom Assessment using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients treated with Talquetamab

P-145: Innovative AI-Driven Decision Support Tool for Multiple Myeloma using Retrieval Augmented Generation

P-146: Measuring symptom improvement in idiopathic multicentric Castleman disease: Protocol for a novel outcome measure

P-147: Central Nervous System Involvement in Multiple Myeloma Cases Reported at Instituto Nacional de Cancerología

P-148: Approach to Diagnosis and Management of multiple myeloma-related bone disease in Latin America, a GELAMM survey.

P-149: WHOLE BODY LOW DOSE CT (WBLDCT), AS INITIAL IMAGING MODALITY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EXPERIENCE FROM A TERTIARY CARE CENTER IN NORTH INDIA

P-150: Rapid whole-body PET/MRI with fat-suppressed T2-weighted imaging is superior to whole-body PET/MRI with diffusion-weighted imaging (DWI) in plasma cell disorders

P-151: Dietary oleic acid influences the myeloma immune microenvironment and improves clinical outcomes

P-152: CORRELATION OF THE G8 SCREENING EXAM WITH THE COMPREHENSIVE GERIATRIC ASSESSMENT IN ELDERLY UNDERGOING AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION – EXPERIENCE FROM A SINGLE CENTER IN BRAZIL

P-153: The impact of socioeconomic status on clinical presentation in multiple myeloma

P-154: Multidisciplinary, patient-centric bone disease management in multiple myeloma – A single-centre experience

P-155: Evaluation of pseudo-CT MRI sequences (zero-echo-time (ZTE) and back bone (BB) gradient-echo) for the detection of lytic bone lesions in MM: comparison with PET/CT.

P-156:Cryotherapy Prevents Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation

P-157: Application of the IMWG Frailty Score in Newly Diagnosed Multiple Myeloma Patients in a Brazilian Cohort

P-158: Dengue fever in Multiple Myeloma patients: clinical characteristics and outcomes

P-159: Patient Experiences in Clinical Trials and Expectations from Future Treatments of Multiple Myeloma: Online Survey and Qualitative Interviews in China

P-160: INVESTIGATION OF THE RADIOLOGICAL TECHNIQUES TO DETECT OSTEOLYTIC LESIONS, FRACTURES, AND OSTEOPOROSIS IN MULTIPLE MYELOMA PATIENTS